Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,430,687 papers from all fields of science
Search
Sign In
Create Free Account
RDEA 119
Known as:
MEK Inhibitor RDEA119
, RDEA-119
, RDEA119
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
refametinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 5253: MEK-ERK pathway inhibition reduces mucin production in a murine xenograft model of pseudomyxoma peritonei
H. Choudry
,
A. Mavanur
,
M. O’Malley
,
Z. Guo
,
H. Zeh
,
D. Bartlett
2012
Corpus ID: 76581197
Introduction: Pseudomyxoma peritonei (PMP) is characterized by compressive organ dysfunction from progressive intra-peritoneal…
Expand
2012
2012
Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance
T. Pemovska
,
Evgeny Kylesskiy
,
+21 authors
K. Wennerberg
2012
Corpus ID: 70824727
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Identification of signaling pathways that are…
Expand
2011
2011
Cancer Therapy : Preclinical Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells
Caroline H. Diep
,
R. Muñoz
,
A. Choudhary
,
D. Hoff
,
Haiyong Han
2011
Corpus ID: 33438360
Purpose: The combination of erlotinib and gemcitabine has shown a small but statistically significant survival advantage when…
Expand
2011
2011
Abstract 5470: Potent MEK inhibitor CIP-137401: Preclinical studies
U. Khire
,
A. Bhargava
,
B. Hart
,
M. Chordia
2011
Corpus ID: 71508404
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL In recent years there is a lot of interest in both pre…
Expand
2007
2007
RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer
P. Weingarten
,
R. Hamatake
,
+9 authors
J. Vernier
2007
Corpus ID: 87920134
B120 Introduction: The RAS-RAF-MEK-ERK pathway has emerged as a significant focus for molecular targeted cancer therapy, and MEK…
Expand